TCGA-78-7156-01A-11R-2039-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.460
- OXIDATIVE_PHOSPHORYLATION+0.310
- PROTEIN_SECRETION+0.310
- ADIPOGENESIS+0.270
- BILE_ACID_METABOLISM+0.270
- PANCREAS_BETA_CELLS+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- WNT_BETA_CATENIN_SIGNALING+0.180
- XENOBIOTIC_METABOLISM+0.150
- PEROXISOME+0.130
Top 10 suppressed
- E2F_TARGETS-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- G2M_CHECKPOINT-0.510
- MYC_TARGETS_V2-0.500
- APICAL_SURFACE-0.430
- IL6_JAK_STAT3_SIGNALING-0.430
- ALLOGRAFT_REJECTION-0.420
- INFLAMMATORY_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-03721 | — | cohortA2 | 0.951 |
| 2 | TCGA-78-7167-01A-11R-2066-07 | — | cohortA2 | 0.915 |
| 3 | C3L-01889 | — | cohortA2 | 0.913 |
| 4 | TCGA-86-8281-01A-11R-2287-07 | — | cohortA2 | 0.893 |
| 5 | TCGA-78-7633-01A-11R-2066-07 | — | cohortA2 | 0.889 |
| 6 | SRR4296076 | — | cohortA1 | 0.888 |
| 7 | TCGA-44-6776-01A-11R-1858-07 | — | cohortA2 | 0.877 |
| 8 | TCGA-MP-A5C7-01A-11R-A262-07 | — | cohortA2 | 0.871 |
| 9 | SRR2016961 | — | — | 0.857 |
| 10 | SRR8943006 | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |